Drug Pricing Negotiation
Expert articles and analysis related to drug pricing negotiation.
AI Summary — Last 24 Hours
Drug pricing pressure is centering on the Trump administration’s Most Favored Nation agenda, with manufacturers expected to respond through launch timing, price opacity, and contracting complexity—raising near-term uncertainty for Medicare drug spending forecasts, Part D plan bids, and oncology total-cost-of-care models (MFN analysis). For VBC stakeholders, the immediate issue is not just lower list prices but whether MFN-style benchmarks and IRA negotiation dynamics disrupt rebate flows, formulary design, and evidence-based pathway adherence in high-cost specialty categories such as TKIs, where comparative-effectiveness data continue to shape value assessments and payer coverage decisions (ALK TKI evidence review).
Related Articles
Pharmaceutical Manufacturer response to Most Favored Nation (MFN): Delay, Hide or Confuse?
Today I attended the very interesting ISPOR Health Policy Leadership Exchange (HPLE) in Washington DC on the topic of Most Favored Nation (MFN). There were a number of important points made and I’ll s...
[World Report] India drug shortage leaves doctors rationing chemotherapy
The Iran conflict has disrupted supplies of cisplatin and carboplatin, leading to treatment interruption for patients. Samaan Lateef reports from Mumbai.
Comparative effectiveness of ALK tyrosine kinase inhibitors in ALK-positive non–small cell lung cancer: A systematic review and network meta-analysis.
Comparative effectiveness of ALK tyrosine kinase inhibitors in ALK-positive non–small cell lung cancer: A systematic review and network meta-analysis.  American Society of Clinical Oncology - ASCO
Neoadjuvant tyrosine kinase inhibitor therapy for unresectable locally advanced thyroid cancer: A systematic review and meta-analysis.
Neoadjuvant tyrosine kinase inhibitor therapy for unresectable locally advanced thyroid cancer: A systematic review and meta-analysis.  American Society of Clinical Oncology - ASCO